Opinion

Video

Beyond Glucose Control - The Expanding Role of Incretins in Diabetes and Obesity Management

Author(s):

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE

In this MEDcast episode, Diana Isaacs, PharmD, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, interview Dr Juan Frias to explore the mechanism of GLP-1 and GIP agonists in diabetes and weight management and examine key findings from clinical trials for the latest GLP-1/GIP dual agonist.

1:00 Effect of incretins on blood glucose and body weight

3:24 Evolution of GLP-1 agonists

7:45 Mechanism of tirzepatide- dual GLP-1/GIP agonist

10:35 Overview of SURPASS and SURMOUNT trials for tirzepatide

17:45 Benefits vs. risks of GLP-1 agonists

21:45 Sustainability of weight loss with incretin-based therapies

25:30 Future of metabolic diseases management

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Related Content
FDA Approves Tirzepatide for Obstructive Sleep Apnea in Obesity | Image Credit: US Food and Drug Administration
December 20th 2024

FDA Approves Tirzepatide for Obstructive Sleep Apnea in Obesity

Connor Iapoce
Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
December 16th 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Jörn M. Schattenberg, MD | Credit: LinkedIn
December 15th 2024

Study Highlights Real-World Mortality Rates, Factors Increasing Mortality Risk in MASH

Patrick Campbell
Irl Hirsch, MD | Credit: University of Washington
December 12th 2024

Diabetes Dialogue: Celebrating 25 Years of CGM, with Irl Hirsch, MD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia | Image Credit: US Food and Drug Administration
Published: December 13th 2024 | Updated: December 13th 2024

FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia

Connor Iapoce
Mifepristone Significantly Reduces HbA1c in Treatment Phase of CATALYST | Image Credit: LinkedIn
December 12th 2024

Mifepristone Notably Reduces HbA1c in Treatment Phase of CATALYST Trial

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.